Novel Coronavirus Vaccine Jointly Developed By NIH, Moderna Set To Move To Final Testing; Oxford University’s Candidate Currently In Phase III Tests Worldwide

AP: First COVID-19 vaccine tested in U.S. poised for final testing
“The first COVID-19 vaccine tested in the U.S. revved up people’s immune systems just the way scientists had hoped, researchers reported Tuesday — as the shots are poised to begin key final testing. ‘No matter how you slice this, this is good news,’ Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told the Associated Press. The experimental vaccine, developed by Fauci’s colleagues at the National Institutes of Health and Moderna Inc., will start its most important step around July 27: A 30,000-person study to prove if the shots really are strong enough to protect against the coronavirus…” (Neergaard, 7/14).

Bloomberg Businessweek: Covid Vaccine Front-Runner Is Months Ahead of Her Competition
“…[Sarah Gilbert, professor of vaccinology and researcher with the University of Oxford’s Jenner Institute & Nuffield Department of Clinical Medicine,] has been all over the British press, but she appears to regard public attention as a distraction. For more than two decades she worked anonymously, developing vaccines while also, of necessity, churning out endless grant applications. Her research was rarely discussed outside scientific circles. Now she’s leading one of the most high-profile and advanced vaccine candidates against Covid-19, with Phase III, or final-stage, trials under way involving thousands of people in Brazil, South Africa, the U.K., and, soon, the U.S…” (Baker, 7/15).

Additional coverage of research into a novel coronavirus vaccine and other vaccine-related news is available from Al Jazeera, CBS News, Financial Times, The Hill, NBC News, New York Times, POLITICO, STAT, The Telegraph, UPI, Wall Street Journal, and Washington Post.